In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Guidance programme 1 selected

Guidance programme

Area of interest

Showing 201 to 210 of 301

TitleTypeExpected publication date
Pembrolizumab with lenvatinib and chemotherapy for untreated advanced gastro-oesophageal junction cancer [TSID11861]Technology appraisal guidanceTBC
Pembrolizumab with lenvatinib and chemotherapy for untreated metastatic squamous cell oesophageal cancer [TSID12096]Technology appraisal guidanceTBC
Pembrolizumab with olaparib for treating hormone-relapsed metastatic prostate cancer after abiraterone or enzalutamide and chemotherapy [ID3814]Technology appraisal guidanceTBC
Pertuzumab–trastuzumab with chemotherapy for treating HER2-positive breast cancer [ID2724]Technology appraisal guidanceTBC
Pharmalgen for the treatment of bee and wasp venom allergyTechnology appraisal guidanceTBC
Pimicotinib for treating tenosynovial giant cell tumours when systemic treatment is needed [ID6647]Technology appraisal guidanceTBC
Pirtobrutinib for treating relapsed or refractory chronic lymphocytic leukaemia after a BTK inhibitor [ID6269]Technology appraisal guidanceTBC
Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma [ID3975]Technology appraisal guidanceTBC
Pirtobrutinib for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6397]Technology appraisal guidance
Plozasiran for treating familial chylomicronaemia syndrome [ID6593]Technology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All